Alumis (ALMS.US) Soars Over 154% at Open on Positive Phase 3 Psoriasis Drug Trial Results

Stock News01-06 22:47

On Tuesday, Alumis Inc. (ALMS.US) skyrocketed more than 154% at the opening bell, reaching a record high of $20.60.

The surge followed the company's announcement of positive top-line results from the Phase 3 ONWARD1 and ONWARD2 clinical trials for its drug, envudeucitinib.

Envudeucitinib is a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor intended for patients with moderate to severe plaque psoriasis.

In both the ONWARD1 and ONWARD2 trials, envudeucitinib met all primary and secondary endpoints with a high degree of statistical significance.

In these studies, envudeucitinib demonstrated significantly superior skin clearance compared to a placebo at the 16-week mark for the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 (p < 0.0001).

On average across the ONWARD1 and ONWARD2 trials, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1, with responses deepening over time.

Furthermore, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191699696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191699696","market":"hk","top_or_hot":-1,"title":"Alumis (ALMS.US) Soars Over 154% at Open on Positive Phase 3 Psoriasis Drug Trial Results","media":"Stock News","content":"<p>On Tuesday, Alumis Inc. (ALMS.US) skyrocketed more than 154% at the opening bell, reaching a record high of $20.60.</p>\n<p>The surge followed the company's announcement of positive top-line results from the Phase 3 ONWARD1 and ONWARD2 clinical trials for its drug, envudeucitinib.</p>\n<p>Envudeucitinib is a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor intended for patients with moderate to severe plaque psoriasis.</p>\n<p>In both the ONWARD1 and ONWARD2 trials, envudeucitinib met all primary and secondary endpoints with a high degree of statistical significance.</p>\n<p>In these studies, envudeucitinib demonstrated significantly superior skin clearance compared to a placebo at the 16-week mark for the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 (p < 0.0001).</p>\n<p>On average across the ONWARD1 and ONWARD2 trials, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1, with responses deepening over time.</p>\n<p>Furthermore, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis (ALMS.US) Soars Over 154% at Open on Positive Phase 3 Psoriasis Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis (ALMS.US) Soars Over 154% at Open on Positive Phase 3 Psoriasis Drug Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-06 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Tuesday, Alumis Inc. (ALMS.US) skyrocketed more than 154% at the opening bell, reaching a record high of $20.60.</p>\n<p>The surge followed the company's announcement of positive top-line results from the Phase 3 ONWARD1 and ONWARD2 clinical trials for its drug, envudeucitinib.</p>\n<p>Envudeucitinib is a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor intended for patients with moderate to severe plaque psoriasis.</p>\n<p>In both the ONWARD1 and ONWARD2 trials, envudeucitinib met all primary and secondary endpoints with a high degree of statistical significance.</p>\n<p>In these studies, envudeucitinib demonstrated significantly superior skin clearance compared to a placebo at the 16-week mark for the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 (p < 0.0001).</p>\n<p>On average across the ONWARD1 and ONWARD2 trials, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1, with responses deepening over time.</p>\n<p>Furthermore, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"","article_id":"1191699696","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191699696","pubTimestamp":1767710838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Tuesday, Alumis Inc. (ALMS.US) skyrocketed more than 154% at the opening bell, reaching a record high of $20.60. The surge followed the company's announcement of positive top-line results from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc.","BK4007":"制药"},"translate_title":"Alumis(ALMS.US)因3期银屑病药物试验结果积极而开盘飙升超过154%","themeId":"ff7d18fe305d0508493cad3a6b784395","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1},"content_text":"On Tuesday, Alumis Inc. (ALMS.US) skyrocketed more than 154% at the opening bell, reaching a record high of $20.60.\nThe surge followed the company's announcement of positive top-line results from the Phase 3 ONWARD1 and ONWARD2 clinical trials for its drug, envudeucitinib.\nEnvudeucitinib is a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor intended for patients with moderate to severe plaque psoriasis.\nIn both the ONWARD1 and ONWARD2 trials, envudeucitinib met all primary and secondary endpoints with a high degree of statistical significance.\nIn these studies, envudeucitinib demonstrated significantly superior skin clearance compared to a placebo at the 16-week mark for the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 (p < 0.0001).\nOn average across the ONWARD1 and ONWARD2 trials, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1, with responses deepening over time.\nFurthermore, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191699696","isCrawlerRequest":true}